#DIABR Conference Hashtag

Benefit-Risk Assessment from Inception to Maturation: Aligning Regulatory and Industry Goals

Join FDA, EMA, Health Canada, and other regulatory agencies plus patient, payor, industry, and academic representatives to discuss the progress and application of Benefit-risk assessment throughout the development and post-approval life cycle. The meeting will feature discussion of emerging sponsor and regulator expectations for Benefit-risk assessment during development; practical methods commonly used to characterize benefits, risks, and their balance in the peri-approval period; and communicating complex assessments transparently across the development life cycle.

#DIABR is a conference hashtag submitted by @DrugInfoAssn